Language

CAS No. 103177-37-3 | Pranlukast

Name: Pranlukast CAS No.103177-37-3 MF:C27H23N5O4 MW:481.5 Purity:98% Package: 5g,25g,200g,500g,1kg Worldwide Delivery

Categories：

Other Life Science Chemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 103177-37-3 | Pranlukast

Synonyms:4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyranh;

benzamide,n-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutox;

emihydrate;

N-[4-keto-2-(2H-tetrazol-5-yl)chromen-7-yl]-4-(4-phenylbutoxy)benzamide;

N-[4-oxo-2-(2H-1,2,3,4-tetrazol-5-yl)chromen-7-yl]-4-(4-phenylbutoxy)benzamide

Specification:

ITEMS	SPECIFICATION
CAS	103177-37-3
MF	C27H23N5O4
MW	481.5
Melting point	236-238°C
Boiling point	1.374±0.06 g/cm3
Density	Soluble in DMSO (up to 25mg/ml)
Acidity coefficient	4.96±0.10
Color	White
Solubility	Soluble in DMSO (up to 25mg/ml)
Form	Solid
Storage condition	Sealed in dry,Store in freezer, under -20°C

Antiasthmatic medicine:

Pranlukast is a commonly used respiratory drug. It is an antiasthmatic drug and a cysteinyl leukotriene (LTs) receptor antagonist. It selectively binds to LTC4, LTD4, and LTE4 receptors to antagonize their effects. . The effects and applications are the same as those of zafirlukast. Clinically used to prevent bronchial asthma. Take 225 mg orally once, twice a day, after breakfast and dinner. Gastrointestinal reactions may occur after taking it, including nausea, vomiting, abdominal pain, diarrhea, or constipation. Sometimes, abnormal liver function symptoms such as fever, rash, itching, and elevated serum aminotransferase or bilirubin may be seen. Pregnant women should use with caution, and the elderly should reduce the dosage as appropriate. This product does not relieve asthma attacks that have already occurred.

Package and transportation :

Package: 5g,25g,200g,500g,1kg